Role of De Novo Fatty Acid Synthesis in Intrinsic Activation of EGFR in Cancer

Simple item page
dc.contributor.advisorZhang, Weihua
dc.contributor.committeeMemberKhurana, Seema
dc.contributor.committeeMemberWidger, William R.
dc.contributor.committeeMemberPeng, Huang
dc.creatorBollu, Lakshmi Reddy 1983-
dc.date.accessioned2019-09-17T01:04:11Z
dc.date.available2019-09-17T01:04:11Z
dc.date.createdAugust 2014
dc.date.issued2014-08
dc.date.submittedAugust 2014
dc.date.updated2019-09-17T01:04:11Z
dc.description.abstractDe novo fatty acid synthesis is one of the major upregulated metabolic pathways in cancer. De novo fatty acid synthesis pathway is crucially involved in cell proliferation, survival and drug resistance of cancer cells. This study focused on the role of fatty acid synthesis in intrinsic activation of EGFR and drug resistance in cancer. EGFR is a receptor tyrosine kinase expressed in most human cancers of epithelial origin and advanced cancers. Besides the plasma membranous (pmEGFR) and nuclear localization, EGFR can also exist in mitochondria (mtEGFR). Our studies revealed that EGFR exists in the inner mitochondrial membrane of prostate and breast cancer cells and promotes mitochondrial fusion through increasing the protein levels of PHB2 and OPA1. Interestingly, in this study, we found that activated pmEGFR activates mtEGFR through de novo synthesized palmitate, through palmitoylation, and promotes mitochondrial fusion. Along with mtEGFR, we also found that pmEGFR also undergo de novo fatty acid synthesis dependent palmitoylation which is important for EGFR localization, stability and signaling. We also observed intrinsic activation of EGFR in response to anticancer drugs such as SN38 and oxaliplatin dependent on de novo fatty acid synthesis. Finally, targeting de novo fatty acid synthesis or palmitoylation significantly increased the sensitivity of cancer cells to EGFR TKIs or anticancer drugs. In conclusion, through this study we’ve uncovered the importance of de novo fatty acid synthesis in intrinsic activation and non-classical functions of EGFR in cancer.
dc.description.departmentBiology and Biochemistry, Department of
dc.format.digitalOriginborn digital
dc.format.mimetypeapplication/pdf
dc.identifier.citationPortions of this document appear in: Ren, Jiangong, Lakshmi R. Bollu, Fei Su, Guang Gao, Lei Xu, Wei‐Chien Huang, Mien‐Chie Hung, and Zhang Weihua. "EGFR–SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors." The Prostate 73, no. 13 (2013): 1453-1461.
dc.identifier.urihttps://hdl.handle.net/10657/4750
dc.language.isoeng
dc.rightsThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. UH Libraries has secured permission to reproduce any and all previously published materials contained in the work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).
dc.subjectEGFR
dc.subjectFASN
dc.subjectACLy
dc.subjectDe novo fatty acid synthesis
dc.subjectMitochondrial fusion and drug resistance
dc.titleRole of De Novo Fatty Acid Synthesis in Intrinsic Activation of EGFR in Cancer
dc.type.dcmiText
dc.type.genreThesis
thesis.degree.collegeCollege of Natural Sciences and Mathematics
thesis.degree.departmentBiology and Biochemistry, Department of
thesis.degree.disciplineCell and Molecular Biology
thesis.degree.grantorUniversity of Houston
thesis.degree.levelDoctoral
thesis.degree.nameDoctor of Philosophy

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
BOLLU-DISSERTATION-2014.pdf
Size:
3.68 MB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description:
Download

Collections

Published ETD Collection